Werewolf Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
Werewolf Therapeutics, Inc. filed a Form 8-K dated March 16, 2023, reporting entry into a material amendment to its loan and security agreement with Pacific Western Bank. The filing does not present quarterly or annual financial results.
Material agreement and liquidity terms
- On March 16, 2023, the company entered into a First Amendment to its Amended and Restated Loan and Security Agreement with Pacific Western Bank.
- The amendment permits the company to maintain depository accounts outside Pacific Western Bank, subject to an aggregate limit of $5.0 million.
- Before maintaining any such accounts, the company and Pacific Western Bank must enter into a deposit account control agreement for the applicable accounts.
- The underlying Amended and Restated Loan and Security Agreement was dated April 12, 2022.
Financial performance and outlook
The filing does not provide revenue, profit or loss, cash flow, margins, debt balances, liquidity balances, financial guidance, or operating forecasts. It also does not disclose changes versus a prior comparable period.
Risks, contingencies, and unusual items
The principal disclosed change is the restriction that deposits held outside Pacific Western Bank may not exceed $5.0 million and will require deposit account control agreements. The filing does not describe additional amendments, fees, interest-rate changes, covenant changes, defaults, or other contingencies.
Important facts to verify
- Review Exhibit 10.1 for the complete amendment and any terms not summarized in the Form 8-K.
- Confirm the company’s total deposits maintained outside Pacific Western Bank and compliance with the $5.0 million aggregate limit.
- Review the original April 12, 2022 loan agreement for outstanding borrowings, covenants, collateral, maturity, and default provisions.
- Consult the company’s subsequent periodic filings for the agreement’s effect on debt, liquidity, and cash-management arrangements.